New reimbursement models are coming to cancer diagnostics

A newly proposed payment model aims to increase reimbursement for cancer diagnostics by incentivizing companies to produce more clinical utility data. However, to drive widespread adoption, companies may also need to look to risk-sharing deals with payers.

Molecular diagnostics and sequencing-based tests for cancer have been stuck in a negative loop...